Repligen Corp(RGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:30 PM ET (Korea 9/11 08:30)
Full metrics table
| Index | - | P/E | 224.45 | EPS (ttm) | 0.73 | Insider Own | 5.57% | Shs Outstand | 56.4M | Perf Week | -4.78% |
| Market Cap | 9.29B | Forward P/E | 62.48 | EPS next Y | 27.85% | Insider Trans | -0.43% | Shs Float | 53.3M | Perf Month | -0.05% |
| Enterprise Value | 9.17B | PEG | 2.37 | EPS next Q | 0.46 | Inst Own | 117.46% | Short Float | 11.42% | Perf Quarter | 25.94% |
| Income | 0.04B | P/S | 11.84 | EPS this Y | 20.56% | Inst Trans | 0.41% | Short Ratio | 5.44 | Perf Half Y | 38.12% |
| Sales | 0.79B | P/B | 4.4 | EPS next 5Y | 26.39% | ROA | 1.42% | Short Interest | 6.09M | Perf YTD | 0.5% |
| Book/sh | 37.43 | P/C | 11.47 | EPS past 3/5Y | -35.6% -4.91% | ROE | 1.99% | 52W High | -12.74% ($188.73) | Perf Year | 36.97% |
| Cash/sh | 14.36 | P/FCF | 84.37 | Sales past 3/5Y | -2.7% 15.05% | ROIC | 1.49% | 52W Low | 63.07% ($100.99) | Perf 3Y | 2.02% |
| Dividend Est. | - | EV/EBITDA | 51.28 | EPS Y/Y TTM | 397.9% | Gross Margin | 48.79% | Volatility(W/M) | 4.22% 4.09% | Perf 5Y | -44.18% |
| Dividend TTM | - | EV/Sales | 11.69 | Sales Y/Y TTM | 16.49% | Oper. Margin | 9.03% | ATR (14) | 7.1 | Perf 10Y | 411.59% |
| Dividend Ex-Date | - | Quick Ratio | 7.64 | EPS Q/Q | -66.4% | Profit Margin | 5.29% | RSI (14) | 47.08 | Recom | 1.39 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.05 | Sales Q/Q | 11.93% | SMA20 | -5.05% ($173.44) | Beta | 1.1 | Target Price | $189 |
| Payout | - | Debt/Eq | 0.33 | Earnings | 2026/7/28 | SMA50 | 4.76% ($157.2) | Rel Volume | 0.85 | Prev Close | $165.05 |
| Employees | 2000 | LT Debt/Eq | 0.32 | EPS/Sales Surpr. | 20.81% 1.26% | SMA200 | 15.85% ($142.15) | Avg Volume(3M) | 1.12M | Price | $164.68 |
| IPO | 1986/4/29 | Option/Short | Yes/Yes | Trades | 15726 | Volume | 948,700 | Change | -0.22% |
Company
RGEN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧪 A U.S. life sciences company that supplies process technologies and consumables used in biopharmaceutical production. It provides filtration, purification, analytics, and fluid management solutions needed to manufacture biopharmaceuticals such as antibodies, cell therapies, and gene therapies, positioning it as a medical tools play whose performance is tied to biomanufacturing demand and the expansion of new drug pipelines.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
RGEN makes money exceptionally well
9.03% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.6% this year.
Tap to view numbers
The price looks about right
Trading at 224.4 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +2.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 117.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FBT 0.03%
FRTY 0.03%
TFGZ 0.03%
ASD 0.03%
PBE 0.03%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
ARGT 817MIt ranks #4 in the industry
Based on market cap of $9B.
RGEN $9B PER 224.4
ISRG $127B PER 41.3
BDX $48B PER 53.2
MDLN $43B PER 38.0
FAQ
What kind of company is RGEN?
RGEN belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of RGEN?
The market cap of RGEN is approximately $9.3B, ranking 984 within its sector.
What is the P/E ratio of RGEN?
RGEN has a P/E ratio of approximately 224.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RGEN?
RGEN has recorded a 52-week high of $188.73 and a low of $100.99.
